Jinsheng Huang, Zecong Xiao, Yongcheng An, Shisong Han, Wei Wu, Yong Wang, Yu Guo, Xintao Shuai
Although a combination with photodynamic therapy (PDT) is a potential means to improve the immune checkpoint blockade (ICB)-based anticancer immunotherapy, this strategy is subjected to the extremely poor light penetration in melanoma. Herein, we develop a lipid (LP)-based micellar nanocarrier encapsulating sonosensitizer chlorin e6 (Ce6) in the core, conjugating anti-PD-L1 antibody (aPD-L1) to the interlayer through MMP-2-cleavable peptide, and bearing a PEG coating sheddable at low pH value (≈6.5) of tumor microenvironment...
January 4, 2021: Biomaterials
Mehul D Bhatt, Allison M Perz, Eduardo Moioli, Joseph F Sobanko, Thuzar M Shin, Jeremy R Etzkorn, Rosalie Elenitsas, Emily Y Chu, Harold W Higgins, Cerrene N Giordano, Stacy McMurray, Aimee Krausz, Leora Aizman, Tess M Lukowiak, Christopher J Miller
No abstract text is available yet for this article.
January 13, 2021: Journal of the American Academy of Dermatology
E Nagore, M A Martinez-Garcia, J D Gomez-Olivas, E Manrique-Silva, A Martorell, J Bañuls, C Carrera, P Ortiz, J Gardeazabal, A Boada, E de Eusebio, E Chiner, C Gonzalez, A Pérez-Gil, D Cullen, M Formigón, B de Unamuno, C Navarro-Soriano, A Muriel, D Gozal
BACKGROUND: Some studies have suggested a relationship between type 2 diabetes mellitus (T2DM) and increased incidence of melanoma. Efforts are underway to identify preventable and treatable factors associated with greater melanoma aggressiveness, but no studies to date have examined the relationship between T2DM and the aggressiveness of cutaneous melanoma at diagnosis. OBJECTIVES: To explore potential associations between T2DM, glycaemic control and metformin treatment and the aggressiveness of cutaneous melanoma...
January 16, 2021: British Journal of Dermatology
K Liang Zeng, Arjun Sahgal, Zain A Husain, Sten Myrehaug, Chia-Lin Tseng, Jay Detsky, Arman Sarfehnia, Mark Ruschin, Mikki Campbell, Monica Foster, Sunit Das, Nir Lipsman, Georg A Bjarnason, Eshetu G Atenafu, Pejman Jabehdar Maralani, Hany Soliman
PURPOSE: The concept of a radioresistant (RR) phenotype has been challenged with use of stereotactic body radiotherapy (SBRT). We compared outcomes following SBRT to RR spinal metastases to a radiosensitive cohort. METHODS: Renal cell, melanoma, sarcoma, gastro-intestinal, and thyroid spinal metastases were identified as RR and prostate cancer (PCA) as radiosensitive. The primary endpoint was MRI-based local failure (LF). Secondary endpoints included overall survival (OS) and vertebral compression fracture (VCF)...
January 16, 2021: Journal of Neuro-oncology
Aaron D Stevens, Timothy N J Bullock
Dendritic cells are potently activated by the synergistic action of CD40 stimulation in conjunction with signaling through toll like receptors, subsequently priming T cells. Cancer vaccines targeting the activation of dendritic cells in this manner show promise in murine models and are being developed for human patients. While the efficacy of vaccines based on CD40 and toll like receptor stimulation has been established, further investigation is needed to understand the mechanism of tumor control and how vaccination alters tumor infiltrating immune cells...
January 16, 2021: Cancer Immunology, Immunotherapy: CII
Pengcheng Liu, Ruili Du, Xin Yu
Retraction of this publication has been requested by the authors due to problems with reproducibility. Reference: Pengcheng Liu, Ruili Du, Xin Yu. Ursolic Acid Exhibits Potent Anticancer Effects in Human Metastatic Melanoma Cancer Cells (SK-MEL-24) via Apoptosis Induction, Inhibition of Cell Migration and Invasion, Cell Cycle Arrest, and Inhibition of Mitogen-Activated Protein Kinase (MAPK)/ERK Signaling Pathway Med Sci Monit 2019; 25:1283-1290. 10.12659/MSM.913069.
January 16, 2021: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Gaurav Garg, Paul T Finger, Tero T Kivelä, E Rand Simpson, Brenda L Gallie, Svetlana Saakyan, Anush G Amiryan, Vladimir Valskiy, Kimberly J Chin, Ekaterina Semenova, Stefan Seregard, Maria Filì, Matthew Wilson, Barrett Haik, Josep Maria Caminal, Jaume Catala-Mora, Cristina Gutiérrez, David E Pelayes, Anibal Martin Folgar, Martine Johanna Jager, Mehmet Doğrusöz, Gregorius P M Luyten, Arun D Singh, Shigenobu Suzuki
OBJECTIVE: To analyse ocular and systemic findings of patients presenting with systemic metastasis. METHODS AND ANALYSIS: It is an international, multicentre, internet-enabled, registry-based retrospective data analysis. Patients were diagnosed between 2001 and 2011. Data included: primary tumour dimensions, extrascleral extension, ciliary body involvement, American Joint Committee on Cancer (AJCC)-tumour, node, metastasis staging, characteristics of metastases...
January 15, 2021: British Journal of Ophthalmology
Giuliano Mariani, Renato A Valdés Olmos, Sergi Vidal-Sicart, Harry William Strauss
No abstract text is available yet for this article.
January 15, 2021: Journal of Nuclear Medicine
Benjamin Neuditschko, Lukas Janker, Laura Niederstaetter, Julia Brunmair, Katharina Krivanek, Sivan Izraely, Orit Sagi-Assif, Tsipi Meshel, Bernhard K Keppler, Giorgia Del Favero, Isaac P Witz, Christopher Gerner
The prediction of metastatic properties from molecular analyses still poses a major challenge. Here we aimed at the classification of metastasis-related cell properties by proteome profiling making use of cutaneous and brain-metastasizing variants from single melanomas sharing the same genetic ancestry. Previous experiments demonstrated that cultured cells derived from these xenografted variants maintain a stable phenotype associated with a differential metastatic behavior: The brain metastasizing variants produce more spontaneous micro-metastases than the corresponding cutaneous variants...
March 2020: Molecular & Cellular Proteomics: MCP
Johannes Griss, Guilherme Viteri, Konstantinos Sidiropoulos, Vy Nguyen, Antonio Fabregat, Henning Hermjakob
Pathway analyses are key methods to analyze 'omics experiments. Nevertheless, integrating data from different 'omics technologies and different species still requires considerable bioinformatics knowledge. Here we present the novel ReactomeGSA resource for comparative pathway analyses of multi-omics datasets. ReactomeGSA can be used through Reactome's existing web interface and the novel ReactomeGSA R Bioconductor package with explicit support for scRNA-seq data. Data from different species is automatically mapped to a common pathway space...
December 2020: Molecular & Cellular Proteomics: MCP
Francesca Beretti, Francesca Farnetani, Luca Reggiani Bonetti, Luca Fabbiani, Manuela Zavatti, Antonino Maiorana, Giovanni Pellacani, Tullia Maraldi
BACKGROUND: Melanoma is the leading cause of death due to cutaneous malignancy and its incidence is on the rise. Several signaling pathways, including receptor tyrosine kinases, have a role in the development and progression of melanocytic lesions and malignant melanoma. Among those, the hepatocyte growth factor (HGF)/c-met axis is emerging as a critical player because it can play a role in drug resistance. Indeed, 50% of melanoma patients present BRAF mutations, however, all responders develop resistance to the inhibitors typically within one year of treatment...
January 13, 2021: International Journal of Molecular Sciences
Lourdes Valdivia, Lorena García-Hevia, Manuel Bañobre-López, Juan Gallo, Rafael Valiente, Mónica López Fanarraga
Solid lipid particles (SLPs) can sustainably encapsulate and release therapeutic agents over long periods, modifying their biodistribution, toxicity, and side effects. To date, no studies have been reported using SLPs loaded with doxorubicin chemotherapy for the treatment of metastatic cancer. This study characterizes the effect of doxorubicin-loaded carnauba wax particles in the treatment of lung metastatic malignant melanoma in vivo. Compared with the free drug, intravenously administrated doxorubicin-loaded SLPs significantly reduce the number of pulmonary metastatic foci in mice...
January 13, 2021: Pharmaceutics
Tamiem Adam, Therese M Becker, Wei Chua, Victoria Bray, Tara L Roberts
Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome...
January 13, 2021: Cancers
Brianna D Young, Wenbo Yu, Darex J Vera Rodríguez, Kristen M Varney, Alexander D MacKerell, David J Weber
S100B, a biomarker of malignant melanoma, interacts with the p53 protein and diminishes its tumor suppressor function, which makes this S100 family member a promising therapeutic target for treating malignant melanoma. However, it is a challenge to design inhibitors that are specific for S100B in melanoma versus other S100-family members that are important for normal cellular activities. For example, S100A1 is most similar in sequence and structure to S100B, and this S100 protein is important for normal skeletal and cardiac muscle function...
January 13, 2021: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
William J Phillips, Tabassom Baghai, Michael Ong, Bryan Lo, Andrea M Ibrahim, Tyler K T Smith, Xinni Song
Background: Brain metastases are observed in more than 40% of all patients with stage 4 melanoma. In recent years, more extensive use of stereotactic radiation (STRT) and the advent of immune checkpoint inhibitors have positively impacted outcomes in patients with metastatic melanoma.brain metastases. Here, we examined real world clinical outcomes of patients presenting with melanoma brain metastases (MBMs). Methods: This retrospective review evaluated MBMs patients treated at The Ottawa Hospital from April 2000 to July 2017...
January 13, 2021: Current Oncology
Zena N Willsmore, Ben G T Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, Robert J Harris, Alicia Chenoweth, Jitesh Chauhan, Heather J Bax, Alexa McCraw, Anthony Cheung, Gabriel Osborn, Ricarda M Hoffmann, Mano Nakamura, Roman Laddach, Jenny L C Geh, Alastair MacKenzie Ross, Ciaran Healy, Sophia Tsoka, James F Spicer, Debra H Josephs, Sophie Papa, Katie E Lacy, Sophia N Karagiannis
Cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and the Programmed Death Receptor 1 (PD-1) are immune checkpoint molecules that are well-established targets of antibody immunotherapies for the management of malignant melanoma. The monoclonal antibodies Ipilimumab, Pembrolizumab and Nivolumab, designed to interfere with T-cell inhibitory signals to activate immune responses against tumours, were originally approved as monotherapy. Treatment with a combination of immune checkpoint inhibitors may improve outcomes compared to monotherapy in certain patient groups and these clinical benefits may be derived from unique immune mechanisms of action...
January 15, 2021: European Journal of Immunology
Joseph N Mehrabi, Kristen M Kelly, Jon D Holmes, Christopher B Zachary
BACKGROUND AND OBJECTIVE: Long-term benefits can be predicted by the incorporation of more intelligent systems in lasers and other devices. Such systems can produce more reliable zones of thermal injury when used in association with non-invasive monitoring and precise laser energy delivery. The more classical endpoint of tumor destruction with radiofrequency or long-pulsed (LP) 1064 nm laser is the non-specific appearance of tissue graying and tissue contraction. Herein we discuss combining non-invasive LP 1064 nm Nd:YAG treatment with the assistance of optical coherence tomography (OCT) and the forward-looking infrared (FLIR) thermal camera while testing literature-based formulae for thermal destruction...
January 15, 2021: Lasers in Surgery and Medicine
Arjun Khunger, Ghanashyam Sarikonda, Jennifer Tsau, Anil Pahuja, Zeni Alfonso, Jane Gao, Christian Laing, Christine Vaupel, Naveen Dakappagari, Ahmad A Tarhini
Neoadjuvant therapy with ipilimumab in combination with high dose IFNα was evaluated in patients with locally/regionally advanced melanoma in a previously reported clinical trial [NCT01608594]. In this study, peripheral immune cell profiling was performed in order to investigate the underlying mechanisms of tumor immune susceptibility and resistance. Peripheral blood mononuclear cells (PBMCs) from treated patients (N = 28) were collected at baseline and then at 6-weeks, 3-months and 12-months. High complexity (14-color) flow cytometry, designed to detect key immunological biomarkers was used to evaluate the frequencies of immune cell subsets...
January 12, 2021: Translational Oncology
Tithi Roy, Samuel T Boateng, Sergette Banang-Mbeumi, Pankaj K Singh, Pratik Basnet, Roxane-Cherille N Chamcheu, Federico Ladu, Isabel Chauvin, Vladimir S Spiegelman, Ronald A Hill, Konstantin G Kousoulas, Bolni Marius Nagalo, Anthony L Walker, Jean Fotie, Siva Murru, Mario Sechi, Jean Christopher Chamcheu
Due to hurdles, including resistance, adverse effects, and poor bioavailability, among others linked with existing therapies, there is an urgent unmet need to devise new, safe, and more effective treatment modalities for skin cancers. Herein, a series of flavonol-based derivatives of fisetin, a plant-based flavonoid identified as an anti-tumorigenic agent targeting the mammalian targets of rapamycin (mTOR)-regulated pathways, were synthesized and fully characterized. New potential inhibitors of receptor tyrosine kinases (c-KITs), cyclin-dependent kinase-2 (CDK2), and mTOR, representing attractive therapeutic targets for melanoma and non-melanoma skin cancers (NMSCs) treatment, were identified using inverse-docking, in vitro kinase activity and various cell-based anticancer screening assays...
December 30, 2020: Bioorganic Chemistry
Franziska K Krebs, Emily R Trzeciak, Sophia Zimmer, Deniz Özistanbullu, Heidrun Mitzel-Rink, Markus Meissner, Stephan Grabbe, Carmen Loquai, Andrea Tuettenberg
BACKGROUND: Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS: This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanoma patients prior to ICI therapy was analyzed by flow cytometry and complete blood count...
January 15, 2021: Cancer Medicine
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"